Mechanistically, CASE modulated TGF-β/Smad signaling pathway and inhibited TGF-β–specific target gene expression in liver fibrosis and hepatocellular carcinoma, whereas the amelioration of hepatoma phenotypic hallmarks was verified (Boye et al., 2015). Here, TGFB1 is linked to Hepatic fibrosis.